The present study supports the hypothesis that modulation of the sphingolipid pathway via inhibition of de novo GlcCer synthesis by brain-penetrant GCS inhibitors can ameliorate the proteinopathy and cognitive impairment phenotypes associated with synucleinopathies. Here, UGCG is linked to synucleinopathy.